Glutamate and GABA are often described as functional opposites, although their biology is considerably more complex than a simple “accelerator and brake” analogy. Glutamate is the brain’s principal excitatory neurotransmitter, helping nerve cells transmit signals and supporting processes such as learning, memory, synaptic plasticity and early neural development. GABA, or gamma-aminobutyric acid, is the main inhibitory neurotransmitter in the mature brain, reducing the likelihood that neurons will fire. During development, however, GABA signaling can behave differently from its role in adulthood. Because autism involves diverse patterns of brain development, communication, sensory processing and behavior, changes affecting either signaling system could plausibly influence different aspects of the condition.

The crucial issue is that genes associated with glutamate or GABA do not automatically prove that either neurotransmitter causes a particular trait. A genetic variant may affect several biological pathways at once, occur near multiple genes, or be linked to a broader inherited profile that influences both brain measures and behavior. Researchers therefore need methods capable of distinguishing a direct biological pathway from a coincidental statistical association. The study’s focus on “differing causal roles” signals an effort to examine whether glutamate-related and GABA-related genetic influences contribute to autism through distinct routes rather than treating neurotransmitter biology as one undifferentiated mechanism.

One approach used increasingly in this field is genetic causal inference, including methods related to Mendelian randomization. These techniques use naturally occurring genetic variants as instrumental variables. If a variant is known to influence a biological exposure—such as the regulation of a neurotransmitter-related gene—and that same variant is associated with an outcome, researchers can test whether the pattern is consistent with a causal relationship. The logic depends on demanding assumptions: the genetic instrument must be reliably connected to the exposure, must not be strongly related to confounding factors, and should influence the outcome primarily through the pathway under investigation. These conditions are difficult to satisfy perfectly, but they can provide a valuable framework for moving beyond conventional observational associations.

In autism genetics, such analysis is especially important because the condition is highly heterogeneous. Autism is not one uniform biological entity with a single pathway or a single behavioral profile. Hundreds of genes have been implicated, and their effects may involve synaptic communication, neuronal development, chromatin regulation, immune signaling and other processes. Even when two individuals share an autism diagnosis, the genetic architecture underlying their traits may be substantially different. A comparison between glutamate- and GABA-related genes could therefore help clarify whether these systems are connected to different dimensions of brain structure, brain activity or behavior, rather than contributing in identical ways across all individuals.

The brain-related outcomes considered in research of this kind may include measurable features derived from neuroimaging, electrophysiology or other biological datasets, while behavioral outcomes can encompass cognitive, social, emotional or developmental traits. The value of examining several outcomes at once is that it allows scientists to search for patterns. If genetic influence associated with glutamate consistently aligns with one class of neural or behavioral characteristics, while GABA-related influence aligns with another, that contrast could suggest pathway-specific biology. It would not mean that one neurotransmitter “causes autism” or that the two systems operate independently. Instead, it could indicate that distinct molecular networks make different contributions to a wide spectrum of traits.

A major technical challenge is pleiotropy, the phenomenon in which a single genetic variant affects multiple traits or pathways. Pleiotropy can make a causal estimate appear stronger than it truly is, because the genetic signal may reach the outcome through an alternative route. Researchers must also contend with linkage disequilibrium, in which nearby genetic variants are inherited together, and with tissue specificity, since a gene’s activity in the brain may differ from its activity elsewhere in the body. Differences in developmental timing add another layer of complexity: a gene may influence early neural patterning, later synaptic refinement or adult brain function in ways that cannot be captured by one measurement. These limitations make careful interpretation essential.

The study’s significance lies partly in its attempt to organize a complicated biological landscape into testable causal hypotheses. Rather than asking only whether glutamate or GABA genes are statistically associated with autism, the research asks whether their effects on brain and behavior can be estimated separately. That distinction may eventually help explain why broad theories such as an imbalance between excitation and inhibition have been appealing but difficult to validate. Excitation and inhibition are not controlled by single switches; they emerge from interconnected neurons, receptors, transporters, enzymes, developmental processes and feedback circuits. Genetic evidence that distinguishes individual pathways could make future experiments more precise.

Any clinical implications remain necessarily cautious. A genetic estimate of causal influence is not the same as a treatment recommendation, and it does not establish that altering glutamate or GABA signaling would improve outcomes for autistic people. Neurotransmitter systems are distributed throughout the brain and body, and changing them broadly could produce effects unrelated to the traits researchers hope to modify. The greatest near-term value of this work may be conceptual: identifying which biological relationships deserve laboratory investigation and which popular explanations require refinement. It may also encourage researchers to study autism as a collection of overlapping molecular and developmental pathways rather than as a disorder governed by one universal mechanism.

As autism genetics moves toward increasingly detailed analyses, studies such as this one illustrate a broader shift in neuroscience—from cataloging associations to testing causal architecture. The work by Hollestein, Claassen, Naaijen and colleagues places glutamate and GABA genes into that more demanding framework, examining how inherited molecular differences may relate differently to the brain and to behavior. The results will need to be evaluated alongside experimental studies, longitudinal research and the lived diversity of autistic people. But by separating two central neurotransmitter systems and asking what each may contribute, the study offers a sharper way to investigate one of neuroscience’s most persistent questions: how do genetic instructions become distinct patterns of human brain development and behavior?

Subject of Research: The differing causal roles of glutamate- and GABA-related genes in brain characteristics and behavior associated with autism.

Article Title: Estimating differing causal roles of glutamate and GABA genes on brain and behavior in autism.

Article References: Hollestein, V., Claassen, T., Naaijen, J. et al. “Estimating differing causal roles of glutamate and GABA genes on brain and behavior in autism.” Translational Psychiatry (2026). https://doi.org/10.1038/s41398-026-04361-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04361-3

Keywords: Autism, glutamate, GABA, neurotransmitters, genetics, causal inference, brain development, behavior, neurodevelopmental science, psychiatric genetics

Phelan-McDermid syndrome arises from deletions or mutations of the SHANK3 gene on chromosome 22, a gene critically involved in synaptic function and neurodevelopment. These genetic alterations impair neural connectivity and contribute to a spectrum of symptoms, including intellectual disabilities, developmental delays, and a high incidence of ASD traits. Up to 1% of ASD cases are linked to SHANK3 abnormalities, positioning PMS as a crucial subtype within autism genetics.

The research team integrated data across multiple sources, including genetic testing laboratories and autism research consortia. By compiling data sets from GeneDx, LabCorp, Ambry Genetics, the SPARK study, and the Autism Sequencing Consortium, they created a comprehensive prevalence model. This multisource approach allowed them to adjust for undiagnosed individuals, limitations in current genetic testing methodologies, and those with PMS who do not meet ASD criteria, leading to more accurate population estimates.

One striking implication of the study is the recognition of underutilization of genetic testing among individuals with developmental disabilities and autism. Barriers such as insurance restrictions and insufficient gene coverage in common panels contribute to a large number of undiagnosed cases. As a result, tens of thousands of Americans likely live with PMS without a formal genetic diagnosis.

Experts emphasize that genetic diagnosis is pivotal as therapeutic strategies begin to emerge. Advances in precision medicine target the molecular mechanisms underlying PMS, and clinical trials investigating these approaches are actively ongoing. Precision diagnostics will enable more effective patient stratification and accelerate the development of disease-modifying treatments.

The study arrives at a critical juncture, underscoring the necessity for broader access to comprehensive genetic testing in neurodevelopmental disorders. Identifying individuals with PMS not only facilitates personalized clinical care and informs family counseling, but also expands participation in research and clinical trials. Consequently, the findings bolster advocacy efforts to promote genetic screening as a frontline diagnostic tool for autism spectrum disorders.

In summary, this landmark research enhances understanding of PMS’s true impact and calls for systemic improvements in genetic testing practices. As innovative therapies advance, ensuring accurate and timely diagnosis will be essential to translating molecular discoveries into meaningful clinical benefits for affected individuals and families.

Subject of Research: People
Article Title: Prevalence of Phelan McDermid Syndrome Estimated To Be ~1:7300 Using a Multisource Model
News Publication Date: July 9, 2026
Web References: https://onlinelibrary.wiley.com/doi/10.1002/aur.70297
References: 10.1002/aur.70297
Keywords: Phelan-McDermid syndrome, SHANK3, autism spectrum disorder, genetic testing, neurodevelopmental disorders, precision medicine, prevalence